Biomarker Discovery, Biopharmaceutical R&D Unit, GlaxoSmithKline, Stevenage, SG1 2NY, Hertfordshire, UK.
Curr Opin Pharmacol. 2011 Oct;11(5):549-56. doi: 10.1016/j.coph.2011.06.009.
Monitoring gene expression through the dual approaches of transcriptomics (RNA profiling) and proteomics (protein profiling) has become a key component in our efforts to understand complex biological processes. From the molecular stratification of disease states and the selection of potential drug targets, to patient selection and the confirmation of engagement of pharmacology in clinical studies, we are seeing the impact of gene expression profiling across all phases of the drug discovery process. Ongoing technological advances have driven an expansion in the use of these techniques, demonstrated utility in preclinical and clinical settings and increased regulatory and clinical acceptance. As technologies continue to advance apace, gene expression profiling is likely to play an increasingly important role in the future development of drug discovery.
通过转录组学（RNA 谱分析）和蛋白质组学（蛋白质谱分析）的双重方法监测基因表达已成为我们理解复杂生物过程的关键组成部分。从疾病状态的分子分层和潜在药物靶点的选择，到患者选择和确认药理学在临床研究中的参与，我们都可以看到基因表达谱分析在药物发现过程的所有阶段的影响。不断的技术进步推动了这些技术的广泛应用，在临床前和临床环境中证明了其效用，并提高了监管和临床接受度。随着技术的持续快速发展，基因表达谱分析可能在药物发现的未来发展中发挥越来越重要的作用。
